Repligen Co. (NASDAQ:RGEN) Receives $196.70 Average PT from Analysts

Shares of Repligen Co. (NASDAQ:RGEN - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the nine research firms that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $196.70.

RGEN has been the subject of a number of analyst reports. JPMorgan Chase & Co. upped their price objective on shares of Repligen from $170.00 to $210.00 and gave the stock an "overweight" rating in a research report on Wednesday, December 20th. Stifel Nicolaus upped their price target on shares of Repligen from $165.00 to $207.00 and gave the stock a "buy" rating in a research report on Thursday, February 22nd. Finally, KeyCorp upped their price target on shares of Repligen from $210.00 to $220.00 and gave the stock an "overweight" rating in a research report on Thursday, February 15th.

Insider Activity at Repligen

In related news, Director Karen A. Dawes sold 1,000 shares of the company's stock in a transaction dated Tuesday, February 27th. The shares were sold at an average price of $193.35, for a total transaction of $193,350.00. Following the completion of the sale, the director now owns 87,367 shares of the company's stock, valued at approximately $16,892,409.45. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In related news, COO James Bylund sold 4,373 shares of the company's stock in a transaction dated Friday, February 23rd. The shares were sold at an average price of $198.08, for a total transaction of $866,203.84. Following the completion of the sale, the chief operating officer now owns 14,135 shares of the company's stock, valued at approximately $2,799,860.80. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Karen A. Dawes sold 1,000 shares of the company's stock in a transaction dated Tuesday, February 27th. The shares were sold at an average price of $193.35, for a total transaction of $193,350.00. Following the sale, the director now directly owns 87,367 shares of the company's stock, valued at approximately $16,892,409.45. The disclosure for this sale can be found here. In the last quarter, insiders sold 25,597 shares of company stock valued at $5,039,532. Corporate insiders own 1.10% of the company's stock.

Institutional Trading of Repligen

Hedge funds have recently made changes to their positions in the company. DekaBank Deutsche Girozentrale grew its stake in shares of Repligen by 1.5% in the 3rd quarter. DekaBank Deutsche Girozentrale now owns 10,457 shares of the biotechnology company's stock valued at $1,663,000 after buying an additional 159 shares during the period. American Century Companies Inc. grew its stake in shares of Repligen by 97.5% in the 3rd quarter. American Century Companies Inc. now owns 217,900 shares of the biotechnology company's stock valued at $34,648,000 after buying an additional 107,570 shares during the period. Atria Investments Inc purchased a new stake in shares of Repligen in the 3rd quarter valued at approximately $1,046,000. Nordea Investment Management AB grew its stake in shares of Repligen by 8.9% in the 4th quarter. Nordea Investment Management AB now owns 3,563 shares of the biotechnology company's stock valued at $646,000 after buying an additional 291 shares during the period. Finally, QRG Capital Management Inc. purchased a new stake in shares of Repligen in the 3rd quarter valued at approximately $444,000. Hedge funds and other institutional investors own 97.64% of the company's stock.

Repligen Price Performance

Shares of Repligen stock traded down $4.55 during trading hours on Friday, reaching $171.53. The stock had a trading volume of 706,402 shares, compared to its average volume of 536,121. The stock's 50 day moving average is $192.16 and its 200 day moving average is $173.03. The firm has a market capitalization of $9.58 billion, a PE ratio of 238.24, a PEG ratio of 5.76 and a beta of 1.02. Repligen has a twelve month low of $110.45 and a twelve month high of $211.13. The company has a current ratio of 7.02, a quick ratio of 5.75 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its quarterly earnings data on Wednesday, February 21st. The biotechnology company reported $0.33 earnings per share for the quarter, hitting analysts' consensus estimates of $0.33. The business had revenue of $155.74 million during the quarter, compared to the consensus estimate of $155.38 million. Repligen had a net margin of 6.51% and a return on equity of 5.00%. The company's revenue was down 16.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.68 earnings per share. Equities analysts expect that Repligen will post 1.46 earnings per share for the current fiscal year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.